Clinical Trial Update: AN-PEP on Gluten Exposure in Celiacs [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on AN-PEP for gluten exposure in celiac disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• AN-PEP (Aspergillus niger prolyl endoprotease)

Snippet

Sponsor: Dr. C. Bonorino Udaondo Gastroenterology Hospital | Conditions: Celiac Disease | Phase 4 | Status: COMPLETED